gate phenotype used in the research for osteoporosis. BMD is a complex trait that is influenced by both genetic and environmental factors. Heritability studies in families and studies of twins have shown that genetic factors account for 50%-90% of the variance in BMD [2] [3] [4] [5] [6] . So far, several genes for osteoporosis have been established. These genes include the vitamin D receptor (VDR) gene [7] , estrogen receptor α (ERα) gene [8] , and collagen type Iα1 (COLIA1) gene [9] . We need to clarify more genetic factors of BMD, considering the polygenetic nature of BMD distribution and the multiplicity of endocrine factors known to regulate bone mass and bone turnover.
OSTEOPOROSIS is a common metabolic skeletal disease. It is mainly characterized by low bone mass and microarchitectural deterioration of bone tissue. There is a consequent increase in fragility, which in turn leads to an increased risk of fracture [1] . Bone mineral density (BMD) is the predominant surro-NOTE ml of complete Dulbecco's Modified Eagle Medium (DMEM) and transfected after 38 h using Fugene HD reagent (Roche, Basel, Switzerland) and LRP5 constructs carrying the SnP in exon 18.
Subjects
The subjects in this study were from the central part of Japan. The baseline examination was conducted after obtaining informed consent from 739 unrelated ambulatory postmenopausal volunteers. Genotypes were analyzed in DnA samples obtained from 739 healthy postmenopausal Japanese women (mean age ± SD; 66.2 years ± 7.4). Exclusion criteria included endocrine disorders such as hyperthyroidism, hyperparathyroidism, diabetes mellitus, liver disease, renal disease, use of medications affecting bone metabolism (e.g., corticosteroids, anticonvulsants, heparin sodium), or unusual gynecologic history. none of the women had a history of taking medicines for treatment of osteoporosis, such as active vitamin D3, bisphophonate, SERM, or calcium. The study was approved by the ethics committees of the university of Tokyo and the Research Institute and Practice for Involutional Diseases.
Measurement of BMD and biochemical markers
The total body BMD (g/cm 2 ) of each participant was measured by dual-energy X-ray absorptiometry using the fast-scan mode (DPX-L; Lunar, Madison, WI). We measured the serum concentration of intactosteocalcin (I-OC) (ELISA; Teijin, Tokyo, Japan), intact parathyroid hormone (PTH), and calcitonin (CT). We also determined the urinary ratio of urinary deoxypyridinoline (DPD; HPLC method) to creatinine. The BMD data were recorded as "Z scores"; that is, deviation from the weight-adjusted average BMD for each age. The Z scores were calculated using installed software (Lunar DPX-L) on the basis of data from 20,000 Japanese women.
Determination of a SNP in the LRP5 gene
We determined the A1330V (c.3989C>T) polymorphism of the LRP5 gene using the TaqMan (Applied Biosystems) polymerase chain reaction (PCR) method [20] . To determine the LRP5 SnP, we used an Assayson-Demand SnP Genotyping kit C__25752205_10 in embryonic development and oncogenesis [10, 11] . Studies using Drosophila, Xenopus, and mammalian cells have established a canonical signaling pathway. Wnt proteins bind Frizzled (FZ) proteins and prevent Glycogen synthase kinase 3 (GSk3)-dependent phospholylation of β-catenin, leading to the stabilization of β-catenin. Both genetic and biochemical results have provided evidences indicating that FZ proteins function as Wnt receptors. Furthermore, low-density lipoprotein receptor-related proteins 5 and 6 (LRP5 and LRP6) were also found to be required for Wnt signaling pathway as Wnt coreceptors. Wnt-β-catenin signaling pathway has been shown to regulate bone density through LRP5 [12] [13] [14] [15] . Inactivating mutations in LRP5 decrease the bone mass and cause an autosomalrecessive disorder -osteoporosis-pseudoglioma syndrome-in humans and mice [12, 13] . Meanwhile, activating mutations in LRP5 leads to autosomal-dominant high bone mass traits [14, 15] . These data suggest that LRP5 controls the bone metabolism in vivo in mammals. Moreover, we and several groups have shown that a single nucleotide polymorphism (SnP) located in the exon 18 of the LRP5 gene, caused by an amino acid change (3989C>T, A1330V), is associated with the BMD and incidence of fracture [16] [17] [18] [19] . These data suggest that the A1330V variation in the LRP5 gene may affect the pathogenesis of osteoporosis through decreasing Wnt activity. However, the functional basis of the A1330V variation remains unclear. In the present study, we analyzed the effect of this A1330V variation on Wnt activity. Moreover, in the previous reports which analyzed the association between the A1330V polymprphism and BMD, BMD was measured at the lumbar spine, the femoral neck and the trochanter but not at the total body. Thus, we here investigate the association of the A1330V polymorphism, with total body BMD using 739 postmenopausal women.
Materials and Methods

In vitro activity of the A1330V SNP in the LRP5 gene
We used the Lef-TCF sensitize transcription assay to evaluate canonical Wnt3a signaling that was mediated by the wild-type LRP5 or by the V1330 LRP5 variant. HEk293T cells were seeded at a density of 8 × 10
4 cells/well in 24-well tissue culture plates in 0.5 in 739 postmenopausal Japanese women using the TaqMan methods. Among the 739 postmenopausal women, 355 were AA homozygotes, 318 were AV heterozygotes, and 66 were VV homozygotes. The genotype distribution was found to be in HardyWeinberg equilibrium.
The kruskal-Wallis test revealed that there was a significant association between the A1330V genotype and total body BMD ( Fig. 2A and Table 1 , P = 0.0069). We also compared the Z scores for total body BMD between the subjects bearing at least 1 A allele (AA + AV) and the subjects without the A allele (VV) using an unpaired t-test. Those with the VV genotype had significantly lower Z scores for total body BMD (Z score; AA + AV vs. VV; 0.50 ± 1.07 vs. 0.23 ± 0.98; P = 0.0045) (Fig. 2B , Table 1 ). The background and biochemical data are shown in Table 1 . kruskalWallis test also revealed a significant association between the A1330V genotype and the serum levels of intact osteocalcin (Table 1 , P = 0.029). The other background and biochemical data among the A1330V genotypes were not statistically different.
(Applied Biosystems), which contains sequence-specific forward and reverse primers and 2 TaqMan MGB probes for detecting alleles. During the PCR cycle, 2 TaqMan probes competitively hybridize to a specific sequence of the target DnA and the reporter dye is separated from the quencher dye, resulting in an increase in the fluorescence of the reporter dye. The fluorescence levels of the PCR products were measured with the ABI 7500 Fast Real-Time PCR System (Applied Biosystems), and the 3 different SnP were clearly identified.
Statistical analysis
The Z scores and biochemical markers in the groups of subjects classified by the LRP5 SnP genotypes were compared by the kruskal-Wallis test and unpaired ttest (Student's t-test; StatView-J 4.5). A P value less than 0.05 was considered statistically significant.
Results
Functional significance of the A1330V polymorphism in the LRP5 gene
To evaluate the functional significance of LRP5 alanine to valine at codon 1330, we substituted the alanine at codon 1330 in the wild-type LRP5 (LRP5-A1330) to valine (LRP5-V1330). These LRP5 constructs were transfected in HEk293T cells and measured TCF-Lef reporter activity in response to canonical Wnt3a signaling (Fig. 1.) . Data are shown as relative values compared with the activity in LRP5-A1330 without Wnt3a. The Wnt3a-induced TCF-Lef activity was significantly reduced in the cells containing the LRP5-V1330 than in those containing the wild-type allele (LRP5-A1330 vs LRP5-V1330, 1.900 ± 0.064 vs 1.597 ± 0.101; mean ± SE). In the case of cells not treated with Wnt3a, TCF-Lef activity of cells with LRP5-V1330 was not significantly cahnged as that of those with LRP5-A1330 (LRP5-A1330 vs LRP5-V1330, 1 ± 0.056 vs 0.975 ± 0.015; mean ± SE).
Association between the A1330V polymorphism in the LRP5 gene and total body BMD
We also examined the association between the LRP5-A1330V polymorphism and total body BMD osteophyte formation [16] [17] [18] [19] [21] [22] [23] [24] [25] [26] [27] . These SnPs included 3 nonsynonymous variations: Q89R, V667M, and A1330V. In Caucasian populations, the V667M polymorphism was found to be significantly associated with BMD [22] . Thus far, no studies on V667M have been reported in Asian populations to our knowledge. This could be due to the low minor allele frequency of this SnP in Asian populations. The Q89R polymorphism has been studied only in Asian popula-
Discussion
The discovery of LRP5 as an important regulator in bone metabolism has generated a major interest in the role of LRP5 as a susceptibility gene in the regulation of BMD and/or fracture risk in the general population. Consequently, there have been several recent reports on the association between LRP5 SnPs and different bone phenotypes, including BMD, fracture, and [12] [13] [14] . It had been assumed that the effects of Wnt and LRP5 signaling in bone were caused by direct actions in osteoblast precursors, osteoblasts, and osteocytes [13, [29] [30] [31] . However, a recent report suggests that a key target is the duodenal enterochromaffin cell in mice [32] . In this report, Wnt signaling transduced by LRP5 was assumed to regulate serotonin synthesis, which acts in an endocrine fashion to regulate bone cell metabolism. Previous reports have shown that LRP5 is also required for normal cholesterol and glucose metabolisms in mice model [33, 34] . Moreover, the A1330V polymorphism was found to be associated with the obesity and serum cholesterol levels in human [35] [36] [37] . Thus, it is possible that the association between the A1330V polymorphism and BMD is caused by the other metabolism pathways in an indirect manner.
In conclusion, our findings confirm the findings of the previous studies that the A1330V variant in the LRP5 gene may be a genetic determinant of BMD. The A1330V variant also influences Wnt signaling in vitro. These data suggest that the A1330V variant affects Wnt signaling, which in turn changes the bone metabolism and BMD.
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tions, most likely because of its low frequency in other ethnic groups. Q89R was associated with femoral neck BMD in young korean men [23] and pre-and postmenopausal Chinese women [24] [25] [26] . Q89R was also associated with osteophyte formation in Japanese postmenopausal women [27] . In korean and Chinese populations, strong linkage disequilibrium was observed between Q89R and A1330V. In our previous study, Q89R and A1330V were not in linkage disequilibrium (D' = 0.65, r2 = 0.08) [17] .
The association between the A1330V polymorphism of the LRP5 gene and BMD has been studied in several groups [18] [19] [20] [21] . In these studies, BMD was measured at the lumbar spine, the femoral neck, and the trochanter, however, the total body BMD was not measured. We previously showed that an SnP at the intron 17 (IVS17-1677C>A) in the LRP5 gene was found to be related to total body BMD in 306 Japanese subjects [23] . We have also shown that the IVS17-1677C>A SnP and the A1330V SnP were in strong linkage disequilibrium (D' = 0.99, r2 = 0.98) [17] . These data suggest that the A1330V SnP is also associated with total body BMD. In the present study, the LRP5 A1330V polymorphism was found to be related to total body BMD in 739 Japanese women.
Intact osteocalcin, a bone turnover marker, was significantly associated with the LRP5 A1330V polymorphism, with higher values in the VV than in the AA group. The mean value of urinary deoxypyridinoline, another bone turnover marker, in the VV group was higher than in the AA group, although it did not reach statistical significance. These data suggest that VV genotype increased the bone turnover followed by the low BMD.
The A1330V polymorphism modifies the amino acid sequence of the LRP5 protein. The A1330V polymorphism lies within the second LDL repeat of LRP5. Although the function of this region is unclear, similar domains in the LDL receptors are known to be involved in ligand binding [28] . In the present study, we investigated that the A1330V change decreased li- 
